Cover Image
市場調查報告書

心臟生物標記的全球市場:考察、機會、分析、市場佔有率,及預測

Global Cardiac Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 - 2022

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 361000
出版日期 內容資訊 英文 140 Pages
商品交期: 請詢問到貨日
價格
Back to Top
心臟生物標記的全球市場:考察、機會、分析、市場佔有率,及預測 Global Cardiac Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 - 2022
出版日期: 2016年06月08日 內容資訊: 英文 140 Pages
簡介

全球心臟生物標記市場規模,預計從2016年到2022年以19.5%的年複合成長率推移,到2022年達到22億2,590萬美元。

本報告提供全球心臟生物標記市場相關分析,今後的市場規模、成長率預測,各檢驗地方、類型、應用領域詳細趨勢,主要企業簡介與市場佔有率,各地區、主要國家市場結構、趨勢預測等調查評估。

第1章 簡介

第2章 市場概要

  • 市場定義和範圍
  • 主要調查結果
  • 參數分析
  • 主要市場考察
    • 新興各國前3名
    • 收益生成區分前3名
    • 成長市場、新興趨勢前3名
    • 地區前3名
  • 競爭環境
    • 市場佔有率分析
    • 主要的成功策略
    • 案例研究:市場競爭的主要的動向
  • 波特的五力分析
  • 主要的購買標準
  • 策略性建議
  • 結論

第3章 市場決策要素

  • 推動市場要素
    • 心血管疾病的罹患率的增加
    • 符合成本效益的設備
    • 非侵襲手法
    • 預測的準確度
    • 對臨床實驗有助於
    • 多應用
    • 使用心臟生物標記組合的技術進步
    • 照護現場 (POC) 應用的增加
  • 阻礙市場要素
    • 政府法規
    • 在結果的確認
    • 複雜的製造工程
  • 市場機會
    • 個體化醫療的需求
    • 使用心臟生物標記的照護現場 (POC) 檢驗
    • 新的心臟生物標記的未來發展
  • 市場課題
    • 臨床性有效性的認證、生物標記型實驗的有效利用
  • 母體市場
  • 競爭市場
  • 替代市場

第4章 市場區隔

  • 各檢驗地方
    • 照護現場(POC)
    • 實驗室檢驗
  • 各類型
    • 肌酸激酶 (CK-MB)
    • 肌鈣蛋白 (T, I)
    • 肌紅蛋白
    • 鈉利尿肽 (BNP、NT-PROBNP)
    • 缺血變更白蛋白
    • 其他
  • 各應用領域
    • 心肌梗塞
    • 充血性心臟衰竭
    • 急性冠狀動脈症候群 (ACS)
    • 動脈粥狀硬化
    • 其他

第5章 地區分析

  • 北美的心臟生物標記市場
    • 美國
    • 加拿大
  • 歐洲的心臟生物標記市場
    • 英國
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 其他
  • 亞太地區的心臟生物標記市場
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 其他
  • 其他的國家 (RoW)的心臟生物標記市場
    • 南美
    • 中東、北非 (MENA)
    • 非洲

第6章 企業簡介

  • ABBOTT DIAGNOSTICS
  • ALERE INC.
  • BECKMAN COULTER
  • BECTON, DICKINSON AND CO.
  • BG MEDICINE INC.
  • BIOMERIEUX
  • EKF DIAGNOSTICS HOLDINGS, INC.
  • MERCK & CO, INC.
  • RADIOMETER MEDICAL
  • RANDOX LABORATORY
  • RESPONSE BIOMEDICAL
  • ROCHE HOLDING AG
  • SIEMENS HEALTHCARE
  • SINGULEX
  • THERMO FISHER SCIENTIFIC

圖表一覽

目錄
Product Code: HME-1521015

The global cardiac biomarker market is expected to generate the revenue of $2,225.9 million by 2022, registering a CAGR of 19.5% from 2016 to 2022. The prevention of cardiac diseases, by active monitoring the heart conditions by using cardiac biomarker testing is the newest approach for obtaining fastest output of immediate diagnosing and treatment of cardiac deceases. Cardiac biomarkers are made by protein-based traceable substances used as an indicator to assess biological state and for diagnosing the proactive purposes associated with heart. Cardiac biomarkers are also used as risk calculation for various cardiovascular diseases (CVDs), including myocardial congestive heart failure, infraction, acute coronary syndrome (ACS) among others deceases.

The promising features of markers such as high accuracy, rapid outcomes and affordable pricing of cardiac point of care (POC) testing is supporting the market of cardiac biomarker for the growth, worldwide. To keep the momentum stable of cardiac marker tests, the key manufacturers offers customized solutions. However, limited availability in some cases and side effects such as skeletal muscle injury is hindering the growth of cardiac biomarkers market. However, concerns related to single measurement cardiac biomarkers, high pricing of the devices and certain government regulations is expected to restrain the market to grow.

The global cardiac biomarkers market is basically segmented on the basis of type, application, location of testing and geography. Based on type of cardiac biomarkers, the market is divided into Creatine Kinase (CK-MB), Troponins T and I, myoglobin, BNPs, IMA and others. Troponins I and T are the largest revenue-generating segment in the overall cardiac biomarkers market because of its prodigious specialty and its ability to detect accurately the cardiac events of Acute Coronary Syndrome (ACS).

Based on application segment, the market is subdivided into myocardial infarction, congestive heart failure, atherosclerosis acute coronary syndrome, and others. Myocardial infarction (MI) accounts the highest market share in the global cardiac biomarker market and it is followed by acute coronary syndrome (ACS) because of its highest prevalence rate in all the cardiovascular diseases (CVDs). The location of testing segment is classified under point of care testing and laboratory testing. Doctors and clinicians majorly use point of care cardiac testing for quick monitoring and diagnosing patients with having chest pain in an emergency care unit, therefore, it accounts for the fastest growing CAGR in the forecasted period. However, laboratory testing segment is generating larger revenue in comparison to point of care testing now-a-days.

On the basis of geography, the global cardiac biomarker market is divided into North America, Europe, Asia-Pacific and LAMEA. Out of which North America is leading the global market, owing to the high demand for cardiac testing, high CVD prevalence rates and growing awareness towards cardiac diagnostics solutions. Asia-Pacific is emerging region with fastest growing CAGR due to the modernization in the countries, increasing disposable incomes and increasing affordability for the advanced cardiac treatments.

Key companies working in this market are Roche Diagnostics, Siemens Healthcare, Becton, Alere Inc., BioMerieux, Abbott Laboratories, Bio-Rad Laboratories, Dickinson and Company, Randox laboratories, Beckman Coulter and Thermo Fisher Scientific. Product launch and technological advancements are the few strategies adopted by the key players of global market. Biomarkers production companies are currently focusing on innovative technologies such as automated, multi-assay using combinations of cardiac biomarkers and point-of-care cardiac biomarker devices.

Table of Contents

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. MARKET DEFINITION AND SCOPE
  • 2.2. KEY FINDINGS
  • 2.3. PARAMETRIC ANALYSIS
  • 2.4. KEY MARKET INSIGHTS
    • 2.4.1. TOP 3 EMERGING COUNTRIES
    • 2.4.2. TOP 3 REVENUE GENERATING SEGMENTS
    • 2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS
    • 2.4.4. TOP 3 GEOGRAPHY
  • 2.5. COMPETITIVE LANDSCAPE
    • 2.5.1. MARKET SHARE ANALYSIS
    • 2.5.2. TOP WINNING STRATEGIES
    • 2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES
  • 2.6. PORTER'S FIVE FORCE MODEL
    • 2.6.1. THREAT OF NEW ENTRANTS
    • 2.6.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
    • 2.6.3. BARGAINING POWER OF BUYER
    • 2.6.4. BARGAINING POWER OF SUPPLIER
    • 2.6.5. INTENSITY OF COMPETITIVE RIVALRY
  • 2.7. KEY BUYING CRITERIA
  • 2.8. STRATEGIC RECOMMENDATION
  • 2.9. STRATEGIC CONCLUSIONS

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. RISING PREVALENCE OF CARDIOVASCULAR DISEASES
    • 3.1.2. COST EFFECTIVE DEVICE
    • 3.1.3. NON-INVASIVE METHOD
    • 3.1.4. ACCURACY IN PREDICTION
    • 3.1.5. HELPFUL IN CLINICAL TRIALS
    • 3.1.6. MULTI-APPLICATION
    • 3.1.7. TECHNOLOGICAL ADVANCEMENTS USING CARDIAC BIOMARKERS COMBINATIONS
    • 3.1.8. INCREASING POINT OF CARE (POC) APPLICATION
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. GOVERNMENT REGULATIONS
    • 3.2.2. CONFIRMATION IN RESULT
    • 3.2.3. COMPLEX PRODUCTION PROCESS
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. DEMAND OF PERSONALIZED MEDICINE
    • 3.3.2. POINT OF CARE (POC) TESTING USING CARDIAC BIOMARKERS
    • 3.3.3. FUTURE DEVELOPMENTS IN NOVEL CARDIAC BIOMARKERS
  • 3.4. MARKET CHALLENGES
    • 3.4.1. APPROVAL CLINICAL VALIDITY AND UTILITY OF BIOMARKERS-BASED TESTS
  • 3.5. PARENT MARKET
  • 3.6. COMPETITORS MARKET
  • 3.7. ALTERNATIVE MARKET

4. MARKET SEGMENTATION

  • 4.1. BY LOCATION OF TESTING
    • 4.1.1. POINT OF CARE
    • 4.1.2. LABORATORY TESTING
  • 4.2. BY TYPE
    • 4.2.1. CREATINE KINASE (CK-MB)
    • 4.2.2. TROPONINS(T,I)
    • 4.2.3. MYOGLOBIN
    • 4.2.4. NATRIURETIC PEPTIDES (BNP AND NT-PROBNP)
    • 4.2.5. ISCHEMIA MODIFIED ALBUMIN
    • 4.2.6. OTHERS
  • 4.3. BY APPLICATION
    • 4.3.1. MYOCARDIAL INFARCTION
    • 4.3.2. CONGESTIVE HEART FAILURE
    • 4.3.3. ACUTE CORONARY SYNDROME
    • 4.3.4. ATHEROSCLEROSIS
    • 4.3.5. OTHERS

5. GEOGRAPHICAL ANALYSIS

  • 5.1. NORTH AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.1.1. UNITED STATES (U.S.) CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.1.2. CANADA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 5.2. EUROPE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.2.1. UNITED KINGDOM (UK) CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.2.2. FRANCE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.2.3. GERMANY CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.2.4. SPAIN CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.2.5. ITALY CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.2.6. ROE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 5.3. ASIA PACIFIC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.3.1. INDIA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.3.2. CHINA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.3.3. JAPAN CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.3.4. KOREA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.3.5. AUSTRALIA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.3.6. ROAPAC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 5.4. REST OF THE WORLD CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.4.1. LATIN AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.4.2. MENA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
    • 5.4.3. AFRICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)

6. COMPANY PROFILE

  • 1. ABBOTT DIAGNOSTICS
  • 2. ALERE INC.
  • 3. BECKMAN COULTER
  • 4. BECTON, DICKINSON AND CO.
  • 5. BG MEDICINE INC.
  • 6. BIOMERIEUX
  • 7. EKF DIAGNOSTICS HOLDINGS, INC.
  • 8. MERCK & CO, INC.
  • 9. RADIOMETER MEDICAL
  • 10. RANDOX LABORATORY
  • 11. RESPONSE BIOMEDICAL
  • 12. ROCHE HOLDING AG
  • 13. SIEMENS HEALTHCARE
  • 14. SINGULEX
  • 15. THERMO FISHER SCIENTIFIC

LIST OF TABLES

  • 1. GLOBAL CARDIAC BIOMARKERS MARKET BY LOCATION OF TESTING 2014-2022 ($ MILLION)
  • 2. GLOBAL CARDIAC BIOMARKERS MARKET BY POINT OF CARE 2014-2022 ($ MILLION)
  • 3. GLOBAL CARDIAC BIOMARKERS MARKET BY LABORATORY TESTING 2014-2022 ($ MILLION)
  • 4. GLOBAL CARDIAC BIOMARKERS MARKET BY TYPE 2014-2022 ($ MILLION)
  • 5. GLOBAL CARDIAC BIOMARKERS MARKET BY CREATINE KINASE (CK-MB) 2014-2022 ($ MILLION)
  • 6. GLOBAL CARDIAC BIOMARKERS MARKET BY TROPONINS(T,I) 2014-2022 ($ MILLION)
  • 7. GLOBAL CARDIAC BIOMARKERS MARKET BY MYOGLOBIN 2014-2022 ($ MILLION)
  • 8. GLOBAL CARDIAC BIOMARKERS MARKET BY NATRIURETIC PEPTIDES (BNP AND NT-PROBNP) 2014-2022 ($ MILLION)
  • 9. GLOBAL CARDIAC BIOMARKERS MARKET BY ISCHEMIA MODIFIED ALBUMIN 2014-2022 ($ MILLION)
  • 10. GLOBAL CARDIAC BIOMARKERS MARKET BY OTHERS 2014-2022 ($ MILLION)
  • 11. GLOBAL CARDIAC BIOMARKERS MARKET BY APPLICATION 2014-2022 ($ MILLION)
  • 12. GLOBAL CARDIAC BIOMARKERS MARKET BY MYOCARDIAL INFARCTION 2014-2022 ($ MILLION)
  • 13. GLOBAL CARDIAC BIOMARKERS MARKET BY CONGESTIVE HEART FAILURE 2014-2022 ($ MILLION)
  • 14. GLOBAL CARDIAC BIOMARKERS MARKET BY ACUTE CORONARY SYNDROME 2014-2022 ($ MILLION)
  • 15. GLOBAL CARDIAC BIOMARKERS MARKET BY ATHEROSCLEROSIS 2014-2022 ($ MILLION)
  • 16. GLOBAL CARDIAC BIOMARKERS MARKET BY OTHERS 2014-2022 ($ MILLION)
  • 17. NORTH AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 18. EUROPE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 19. ASIA PACIFIC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 20. REST OF THE WORLD CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CARDIAC BIOMARKERS MARKET BY POINT OF CARE 2014-2022 ($ MILLION)
  • 2. GLOBAL CARDIAC BIOMARKERS MARKET BY LABORATORY TESTING 2014-2022 ($ MILLION)
  • 3. GLOBAL CARDIAC BIOMARKERS MARKET BY CREATINE KINASE (CK-MB) 2014-2022 ($ MILLION)
  • 4. GLOBAL CARDIAC BIOMARKERS MARKET BY TROPONINS(T,I) 2014-2022 ($ MILLION)
  • 5. GLOBAL CARDIAC BIOMARKERS MARKET BY MYOGLOBIN 2014-2022 ($ MILLION)
  • 6. GLOBAL CARDIAC BIOMARKERS MARKET BY NATRIURETIC PEPTIDES (BNP AND NT-PROBNP) 2014-2022 ($ MILLION)
  • 7. GLOBAL CARDIAC BIOMARKERS MARKET BY ISCHEMIA MODIFIED ALBUMIN 2014-2022 ($ MILLION)
  • 8. GLOBAL CARDIAC BIOMARKERS MARKET BY OTHERS 2014-2022 ($ MILLION)
  • 9. GLOBAL CARDIAC BIOMARKERS MARKET BY MYOCARDIAL INFARCTION 2014-2022 ($ MILLION)
  • 10. GLOBAL CARDIAC BIOMARKERS MARKET BY CONGESTIVE HEART FAILURE 2014-2022 ($ MILLION)
  • 11. GLOBAL CARDIAC BIOMARKERS MARKET BY ACUTE CORONARY SYNDROME 2014-2022 ($ MILLION)
  • 12. GLOBAL CARDIAC BIOMARKERS MARKET BY ATHEROSCLEROSIS 2014-2022, ($ MILLION)
  • 13. GLOBAL CARDIAC BIOMARKERS MARKET BY OTHERS 2014-2022 ($ MILLION)
  • 14. NORTH AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 15. UNITED STATES (U.S.) CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 16. CANADA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 17. EUROPE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 18. UNITED KINGDOM (UK) CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 19. FRANCE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 20. GERMANY CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 21. SPAIN CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 22. ITALY CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 23. ROE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 24. ASIA PACIFIC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 25. INDIA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 26. CHINA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 27. JAPAN CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 28. KOREA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 29. AUSTRALIA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 30. ROAPAC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 31. REST OF THE WORLD CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 32. LATIN AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 33. MENA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
  • 34. AFRICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
Back to Top